Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
Teva Pharmaceutical Industries Limited reports developments across its global pharmaceutical business, including complex generic medicines, biosimilars, pharmacy brands, and innovative medicines in neuroscience and immunology. News commonly covers financial results, investor conference presentations, R&D updates, regulatory milestones, and product or patient-support launches tied to brands and candidates such as UZEDY, PONLIMSI, and proposed biosimilars.
As an Israel-based issuer with ADSs traded under TEVA, company updates also address ADR-relevant investor communications, operating outlook materials, partnerships, and strategy around a generics platform supporting a broader biopharmaceutical portfolio.
Teva Pharmaceuticals USA has launched the FDA-approved generic versions of TRUVADA® and ATRIPLA® tablets, marking a significant step in increasing access to HIV treatments. These generics complement Teva's portfolio of over 10 HIV-related medications on the WHO's Essential Medicines list. The new generics provide vital options for the 1.2 million individuals living with HIV-1 in the U.S., as well as addressing the global shortfall of 12.6 million people without access to treatment. The wholesale acquisition cost is set at $48.51 per tablet for Emtricitabine/Tenofovir and $78.86 for the combination tablet.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will release its third quarter financial results on November 5, 2020, at 7:00 a.m. ET. A conference call and live webcast will follow at 8:00 a.m. ET. Participants can join by dialing specified numbers, with a passcode of 7275239. A replay will be available within 24 hours. Teva is a global leader in generic and specialty medicines with over 3,500 products, servicing around 200 million daily users worldwide. The company emphasizes that this release may include forward-looking statements subject to risks and uncertainties.